Major population-based screening trials, such as the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) and the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, found no significant reduction in OC mortality from routine screening using CA125, transvaginal ultrasound (TVUS), or a multimodal strategy [28,29]. This evidence concerns the gene MUC16 and ovarian cancer.